Nerre is an England-based clinical-stage pharmaceutical company that researches and develops neurokinin receptor antagonist drugs to treat cough hypersensitivity disorders... Read more
Nerre is an England-based clinical-stage pharmaceutical company that researches and develops neurokinin receptor antagonist drugs to treat cough hypersensitivity disorders... Read more
News
Jul 13, 2021
Global Legal Chronicle
NeRRe: NeRRe Therapeutics' 20 Million Series B2 Financing Round
Jul 07, 2021
BioSpace
NeRRe: NeRRe Therapeutics raises 20 million in a Series B2 financing round
Jul 07, 2021
MedCity News
NeRRe: NeRRe nabs 20M to test chronic cough drug in patients with a fatal lung disease
Jun 12, 2020
European Biotechnology
NeRRe Therapeutics: NeRRe Therapeutics pushes leads by 26m Series B financing
Jun 08, 2019
BioCentury
Nerre Therapeutics: NeRRe hopes to advance cough candidate despite Phase II miss
Jun 07, 2019
FE Investegate
Nerre Therapeutics: NeRRe Therapeutics : NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
Sep 26, 2017
FierceBiotech
Nerre Therapeutics: NeRRe splits in two, carving out women's health company
Jan 05, 2017
FierceBiotechIT
Nerre Therapeutics: GSK spinout bags £23M to take NK antagonists into phase 2
Jan 04, 2017
THE IRISH TIMES
Nerre Therapeutics: Irish VC leads €27m fundraising for drug targeting hot flushes
Sep 23, 2015
BIOSPACE
Nerre Therapeutics: <b>Dr Mary Kerr</b> To Join <b>NeRRe Therapeutics</b> As CEO
NeRRe Competitors
1
2
3
4
5
6
7
8
9
10